News in the treatment of heart failure - gliflozins in patients with a mildly reduced and preserved ejection fraction
Abstract
Heart failure (HF) with preserved ejection fraction (EF) (HFpEF) have represented until recently a therapeutic challenge with a limited data for medical therapy primarily used in patients with HF with reduced EF (HFrEF). That was reflected by currently applied European and Czech cardiology society guidelines for HF.
Gliflozins, sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors) have been shown in last couple of years as effective and safe therapy in patients with HFrEF. Most recently, two SGLT2i have proven their efficacy even in patients with HFpEF and patients with HF with mildly reduced EF (HFmrEF) in two major clinical trials (EMPEROR-Preserved with empagliflozin and DELIVER with dapagliflozin).
The results of these trials markedly extend our therapeutic options in HFpEF and HFmrEF in diabetic as well as non-diabetic patients and we can expect these results will be reflected by novel updates of guidelines for HF.